Abstracts tagged "Lipids"

Abstract Number: 52 • 2013 ACR/ARHP Annual Meeting
Altered Lipid Metabolism In Osteoarthritis With Subsequent Proinflammatory Properties Of Apolipoprotein A-I
Dominique de Seny¹, Gaël Cobraiville², Edith Charlier³, Sophie Neuville², Laurence Lutteri⁴, Denis Malaise⁵, Olivier Malaise³, Jean-Paul Chapelle⁴, Biserka Relic¹ and Michel G. Malaise¹, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ²GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ⁴Medical Chemistry - CHU Liège, Liège, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: Osteoarthritis (OA) is associated with a local inflammatory process. It is now considered as a metabolic syndrome rather than due to aging or mechanical…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Katherine P. Liao¹, Jonathan Brown², Jonathan S. Coblyn³, Paul Cohen², Jorge Plutzky² and Daniel H. Solomon⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…
Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting
The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis
Hidetake Nagahara¹, Masataka Kohno¹, Ken Murakami¹, Aihiro Yamamoto¹, Takahiro Seno¹, Wataru Fujii¹, Kazuki Fujioka¹, Yuji Kukida¹, Ryo Oda², Hiroyoshi Fujiwara² and Yutaka Kawahito¹, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan
Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…
Abstract Number: 1166 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice
Hajime Kono¹, Tamiko Yanagida², Kurumi Asako¹, Toshihiro Nanki¹, Hirotoshi Kikuchi¹, Akiko Okamoto¹, Akiko Onda³ and Maki Takayama¹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis is a chronic metabolic disease of inflammatory processes. Immune cells including monocytes are recruited to the subintimal lesion of the vascular wall and…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…
Abstract Number: 1249 • 2012 ACR/ARHP Annual Meeting
The Impact of Statin Use On Lipid Levels in Statin-Naive Patients with Rheumatoid Arthritis (RA) Vs. Non-RA Subjects: Results From a Population-Based Study
Elena Myasoedova¹, Cynthia S. Crowson², Abigail B. Green², Eric L. Matteson³ and Sherine E. Gabriel⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Dyslipidemia in patients with rheumatoid arthritis (RA) is well recognized. The impact of lipid-lowering medications on lipid levels in patients with RA vs non-RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].